Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Molecular Partners (NASDAQ:MOLN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025